Why the study?
Does adjuvant chemotherapy containing doxorubicin increase the risk of long-term cardiac sequelae compared to CMF alone in patients with early breast cancer?
Population
1,000 patients with early breast cancer from three prospective trials, including 355 long-term survivors…
Comparison
Adjuvant chemotherapy containing doxorubicin vs Adjuvant chemotherapy not containing anthracycline
Design
Cohort
Follow-up
14 years (median 11 years for cardiac evaluation)
Authors
Loading...
May warrant echocardiographic surveillance after doxorubicin; leaves open net benefit versus CMF in broader early breast cancer populations.
Does adjuvant chemotherapy containing doxorubicin increase the risk of long-term cardiac sequelae compared to CMF alone in patients with early breast cancer?
Long-term follow-up shows that doxorubicin at standard adjuvant doses for early breast cancer causes a small increase in systolic dysfunction but does not lead to significant clinical cardiac sequelae that outweigh its oncologic benefits.
Zambetti et al. (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: